Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > Interference
View:
Post by Jesus4Prez on Jan 09, 2022 4:04pm

Interference

Don mentioned 'interference' playing a part in the slow start of the Covid trial.  It makes me wonder if they might opt not to report first dosing in order to stay under the radar, clear of interference?

J4P
Comment by QualityTest on Jan 10, 2022 8:41am
Don't think so, unforrunately. IR has confirmed to multiple people that we would be notified when dosing commenced.
Comment by narmac on Jan 15, 2022 10:12am
June/2021 News Release:      “With EVERSANA’s integrated commercialization solution, we are poised to swiftly and efficiently deliver apabetalone to patients who desperately need it,” said Donald McCaffrey, President and CEO of Resverlogix. “We are proud to be on the front line with the global scientific medical community as we fight the ongoing threat of this and future pandemics. ...more  
Comment by toinv261 on Jan 15, 2022 1:56pm
It is incredibly pitiful. As 10-41 just posted on Agora other biotechs are making inroads on Covid. I'm beginning to wonder if, because of Don's remarkable incompetence, RVX will ever achieve anything on any indication. The world is competitive and Covid has shown us the remarkable ability of thousands of bright biotech minds to innovate successfully. Don is old, uneducated and not ...more  
Comment by priceless on Jan 16, 2022 11:24am
DM needs a Hail mary pass very very soon, what RVX needs if Covid results are stellar is a media /PR mass media warm room followed up a very large BP partnership ,  DM needs to realize if you can't beat them  ie BP you need to join them,.  BP control everything and Eversan is a good start but may be limited if they can't get a BP partnership deal IMO
Comment by QualityTest on Jan 17, 2022 9:53am
Priceless,  Someone on the Agora board pointed out that one of the PIII advisory council members has been on CNN numerous times dicussing Covid. That's exactly the person we need to make up for IR's weakness. All we need is for him to be on a national US news station and be able to say that we have data proving RVX's effectiveness and we are off to the races.  But WTF is ...more  
Comment by priceless on Jan 17, 2022 10:28am
QT, yes I listened to the Dec webcast and CC, and someone on the RVX  Covid cliical advisory team has been on CNN numerous times in the past few year.  IMO  RVX needs a BP partnership to get the market respect  for valuation .  Everything RVX has tried has not worked even after numrous fantastic peer reviwed publications on several indications plus EVersana partnership ...more  
Comment by QualityTest on Jan 18, 2022 7:51am
We've got liftoff, Priceless!!!!! Best of luck to all that have stuck it out this long.
Comment by priceless on Jan 18, 2022 9:09am
QT If the initial  results are good, with the FDA BTD, lets hope RVX gets a Emergency use authorization,   that will get things moving 
Comment by QualityTest on Jan 18, 2022 9:12am
Couldn't agree more. Am very interested to see if Eversana will be able to get this news on any Canadian channels tonight. 
Comment by priceless on Jan 18, 2022 9:19am
If Eversana can get it on major news networsk, that will 100% light a fire under the stock.....!!
Comment by narmac on Jan 18, 2022 11:32am
Ottawa is busy attepting to negotiate oral pills from Merck and Pfizer!!,, JT will blow his load with BP. Probably little to nothing will be left for a lethargic no namer like RVX. Especially with our track record!!,,,,working around RVX is looked at like being in a sewer. Pinocchio will have 50 patients across the globe to show efficacy in this 2b, Talk about over powered,,,woooooow ...more  
Comment by G1945V on Jan 18, 2022 12:30pm
narmac, let's hope this is not another false start for the open-label Phase 2b study of Apabetalone in Covid infection. Got my fingers crossed. All the best G1945V
Comment by narmac on Jan 18, 2022 6:45pm
GV,,,,,,lets hope is right,,,,,,the market is not putting any speculation into this company because of its inability to prove and provide sharevalue these past 20 years. Nothing will move the share price expept solid numbers of a sort,,something that has been shown to be out of reach for this management team. As Buffet always noted,,,buy the management team of a company who has proven track record ...more  
Comment by narmac on Jan 16, 2022 2:39pm
.,.,,accchhhh,,,Toinv,,,,,,DMcC,,is looked upon as a twin brother to Bernie Madoff,,,I see the resemblance,,,,,, :o) ,,,RVX is a disaster,,,,perhaps one for the record books for management incompentance!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities